Company Valuation: Yabao Pharmaceutical Group Co., Ltd

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 3,835 6,992 4,528 5,215 4,385 4,491
Change - 82.33% -35.24% 15.19% -15.93% 2.42%
Enterprise Value (EV) 1 4,132 7,053 4,301 4,807 3,902 3,707
Change - 70.7% -39.02% 11.77% -18.82% -5%
P/E 35.7x 37.4x 43.3x 26.4x 18.1x 14.2x
PBR 1.38x 2.39x 1.52x 1.74x 1.49x 1.56x
PEG - 0.5x -1x 0.3x 0.6x 0.4x
Capitalization / Revenue 1.47x 2.53x 1.67x 1.79x 1.63x 2x
EV / Revenue 1.59x 2.55x 1.58x 1.65x 1.45x 1.65x
EV / EBITDA 14.4x 19.2x 12.7x 10.8x 9.45x 8.34x
EV / EBIT 35.2x 35.9x 24.1x 16.5x 14.1x 11.9x
EV / FCF 15.7x 25.5x 12.5x 13.4x 11.5x 9.22x
FCF Yield 6.36% 3.92% 8% 7.46% 8.7% 10.8%
Dividend per Share 2 0.05 0.08 0.05 0.15 0.3 0.35
Rate of return 1% 0.88% 0.85% 2.17% 4.93% 5.39%
EPS 2 0.1394 0.243 0.1359 0.2615 0.3356 0.4576
Distribution rate 35.9% 32.9% 36.8% 57.4% 89.4% 76.5%
Net sales 1 2,602 2,764 2,718 2,910 2,686 2,240
EBITDA 1 286.1 366.8 337.4 446.5 412.8 444.5
EBIT 1 117.4 196.7 178.1 291.5 276.8 310.8
Net income 1 107.4 187.1 104.7 199.6 242.7 320
Net Debt 1 297.5 61.69 -226.9 -408.6 -482.9 -784.4
Reference price 2 4.980 9.080 5.880 6.900 6.090 6.490
Nbr of stocks (in thousands) 770,000 770,000 770,000 755,851 720,000 692,000
Announcement Date 4/23/21 4/27/22 4/25/23 4/25/24 4/25/25 4/24/26
1CNY in Million2CNY
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 698M
35.24x6.61x22.91x0.9% 47.86B
18.63x2.22x10.06x1.39% 40.33B
27.99x3.41x17.65x0.9% 12.13B
26.47x3.79x15.71x0.61% 11.5B
18.55x3.29x11.46x3.89% 9.1B
9.76x2.25x5.83x4.43% 7.82B
15.92x2.07x6.74x3.21% 7.22B
29.08x3.8x17.68x0.16% 7.05B
Average 22.70x 3.43x 13.50x 1.94% 15.97B
Weighted average by Cap. 25.50x 4.06x 15.52x 1.48%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. 600351 Stock
  4. Valuation Yabao Pharmaceutical Group Co., Ltd